Document Detail


Use of nifedipine in the hypertensive diseases of pregnancy.
MedLine Citation:
PMID:  7696729     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review the available data about the use of nifedipine to treat hypertension in pregnancy. DATA SOURCES: All English language cases and studies published after 1984 and indexed in MEDLINE, Excerpta Medica, and BIOSIS PREVIEWS under the headings nifedipine, hypertension in pregnancy, uteroplacental blood flow, maternal/fetal hemodynamics, preeclampsia, and pregnancy outcome. MAIN OUTCOME MEASURES: The primary outcome indicators included the safety and antihypertensive efficacy of nifedipine in pregnancy; the effects of nifedipine on maternal/fetal hemodynamics; and the effect, if any, of nifedipine on perinatal outcome. CONCLUSIONS: Tradiational drug therapy choices for hypertension in pregnancy continue to be hydralazine for acute reduction of blood pressure and methyldopa for the management of chronic hypertension. Current data indicate that nifedipine is an appropriate second-line antihypertensive medication in pregnancy, but more clinical trials are needed before it can be considered an appropriate choice for initial therapy. As do other antihypertensive agents, nifedipine provides maternal benefit by lowering blood pressure and reducing the risk of cerebral hemorrhage and end-organ damage. However, perinatal benefit of nifedipine remains to be established.
Authors:
A C Levin; P L Doering; R C Hatton
Related Documents :
1543829 - Drug therapy during pregnancy.
17625709 - Does sodium nitroprusside kill babies? a systematic review.
6422369 - Neurofibromatosis and spontaneous hemothorax in pregnancy: two case reports.
11416689 - Working group report on high blood pressure in pregnancy.
9042089 - Glucose and insulin levels in young subjects with different maternal histories of hyper...
19953259 - Calprotectin, rage and tnf-α in hypertensive disorders in pregnancy: expression and si...
2095289 - Amniotic fluid lysozyme activity in fetal distress.
17411619 - Cost-effectiveness model for first-trimester versus second-trimester ultrasound screeni...
10732119 - Technical and physiological aspects associated with the lower fertilization following i...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  28     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  1994 Dec 
Date Detail:
Created Date:  1995-05-04     Completed Date:  1995-05-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1371-8     Citation Subset:  IM    
Affiliation:
Hillcrest Hospital, Pittsfield, MA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Humans
Hydralazine / pharmacology,  therapeutic use
Hypertension / drug therapy*,  etiology
Nifedipine / administration & dosage,  pharmacology,  therapeutic use*
Pre-Eclampsia / drug therapy
Pregnancy
Pregnancy Complications, Cardiovascular / drug therapy*
Risk Factors
Time Factors
Chemical
Reg. No./Substance:
21829-25-4/Nifedipine; 86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctio...
Next Document:  Beta-agonists in the treatment of acute exacerbation of chronic obstructive pulmonary disease.